A phase II, randomized, controlled, open label, single-center study to evaluate the immunogenicity, safety and tolerability of an H5N1-vaccine and a seasonal influenza vaccine in adult subjects
Phase of Trial: Phase II
Latest Information Update: 01 May 2013
At a glance
- Drugs Influenza A virus vaccine-H5N1; Influenza virus vaccine
- Indications Influenza A virus H5N1 subtype; Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 17 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 31 Jul 2007 New trial record.